Remimazolam - przegląd i wykorzystanie w anestezjologii
Słowa kluczowe:
Remimazolam, anestezjologia, benzodiazepiny, sedacja, anksjolizaStreszczenie
Remimazolam jest lekiem z grupy benzodiazepin, wzbudzającym zainteresowanie ze względu na swoje szybkie działanie i krótki czas trwania efektu, co czyni go atrakcyjnym wyborem w anestezjologii, intensywnej terapii oraz procedurach endoskopowych. Niniejsza monografia ma na celu przegląd dotychczasowej wiedzy na temat remimazolamu z uwzględnieniem jego struktury chemicznej, przez mechanizm działania, farmakokinetykę i farmakodynamikę, aż po potencjalne zastosowania kliniczne i bieżące badania naukowe. Struktura chemiczna omawianego leku oparta na benzodiazepinowym szkielecie, umożliwia jego szybki metabolizm poprzez hydrolizę przez esterazy, co skutkuje krótkim czasem półtrwania. Farmakodynamika remimazolamu polega na pozytywnej modulacji receptorów GABA-A, co prowadzi do hamowania aktywności neuronów, uzyskując efekty uspokajające, anksjolityczne i nasenne. Szybki początek działania i krótki czas trwania efektu czynią go idealnym kandydatem do stosowania w procedurach, gdzie kontrola sedacji jest kluczowa, a szybkie wybudzenie po zakończeniu zabiegu pożądane. Posiada unikalne właściwości farmakokinetyczne i farmakodynamiczne, które pozwalają na dokładną kontrolę sedacji i szybkie wybudzenie, co może przyspieszyć proces rekonwalescencji pacjenta. Aktualnie prowadzone badania kliniczne nad remimazolamem koncentrują się pogłębieniu wiedzy na temat jego skuteczności, bezpieczeństwa oraz potencjalnych zastosowań klinicznych. Obejmują one analizę wpływu remimazolamu na różne grupy pacjentów, porównanie z innymi lekami stosowanymi w anestezjologii oraz identyfikację potencjalnych interakcji z innymi lekami. Wnioski płynące z tej monografii sugerują, że remimazolam może mieć istotny wpływ na praktykę kliniczną, poprawiając jakość opieki nad pacjentami poddawanymi procedurom medycznym, przy jednoczesnym zachowaniu bezpieczeństwa i skuteczności sedacji. Konieczne są jednak dalsze badania, aby w pełni zrozumieć potencjał tego leku i jego miejsce w terapii medycznej.
Bibliografia
J. Wadełek, “A R T Y K U Ł P O G L Ą D O W Y / R E V I E W PA P E R Sedacja i znieczulenie ogólne do endoskopii przewodu pokarmowego Sedation and general anaesthesia for gastrointestinal endoscopy,” vol. 7, pp. 331–340, 2013.
M. Piechota and K. Kusza, “A R T Y K U Ł P O G L Ą D O W Y / R E V I E W PA P E R Standardy postępowania medycznego w dziedzinie anestezjologii i intensywnej terapii Standards of medical treatment in the field of anaesthesiology and intensive therapy,” Anestezjologia i Ratownictwo, vol. 7, pp. 100–112, 2013.
A. Zambouri, “Preoperative evaluation and preparation for anesthesia and surgery,” Hippokratia, vol. 11, no. 1, p. 13, 2007, Accessed: May 23, 2024. [Online]. Available: /pmc/articles/PMC2464262/
A. McCreedy, J. Wacker, R. Ffrench-O’Carroll, K. G. Berthelsen, Z. Kremeňova Tatičová, and A. F. Smith, “Patient safety practices in European anaesthesiology: Expert evaluation and ranking,” Eur J Anaesthesiol, vol. 40, no. 2, pp. 113–120, Feb. 2023, doi: 10.1097/EJA.0000000000001779.
J. D. Tobias, “Preoperative anesthesia evaluation,” Semin Pediatr Surg, vol. 27, no. 2, pp. 67–74, Apr. 2018, doi: 10.1053/J.SEMPEDSURG.2018.02.002.
M. S. KING, “Preoperative Evaluation,” Am Fam Physician, vol. 62, no. 2, pp. 387–396, Jul. 2000, Accessed: May 23, 2024. [Online]. Available: https://www.aafp.org/pubs/afp/issues/2000/0715/p387.html
T. Shiga, Z. Wajima, T. Inoue, and A. Sakamoto, “Predicting difficult intubation in apparently normal patients: A meta-analysis of bedside screening test performance,” Anesthesiology, vol. 103, no. 2, pp. 429–437, 2005, doi: 10.1097/00000542-200508000-00027.
M. Fryer, “Intravenous induction agents,” Anaesthesia & Intensive Care Medicine, vol. 5, no. 9, pp. 317–321, Sep. 2004, doi: 10.1383/ANES.5.9.317.49897.
N. Nathan and I. Odin, “Induction of Anaesthesia,” Drugs 2007 67:5, vol. 67, no. 5, pp. 701–723, Sep. 2012, doi: 10.2165/00003495-200767050-00005.
C. Vanlersberghe and F. Camu, “Propofol,” Handb Exp Pharmacol, vol. 182, pp. 227–252, 2008, doi: 10.1007/978-3-540-74806-9_11.
D. S. Warner et al., “PropofolIts Role in Changing the Practice of Anesthesia,” Anesthesiology, vol. 109, no. 6, pp. 1132–1136, Dec. 2008, doi: 10.1097/ALN.0B013E31818DDBA8.
C. C. Hug et al., “Hemodynamic effects of propofol: data from over 25,000 patients.,” Anesth Analg, vol. 77, no. 4 Suppl, pp. S21-9, Oct. 1993, Accessed: May 23, 2024. [Online]. Available: https://europepmc.org/article/med/8214693?utm_medium=email&utm_source=transaction&client=bot&client=bot&client=bot
“Propofol: An Overview of Its Risks and Benefits. | Compendium of Continuing Education in Dentistry (15488578) | EBSCOhost.” Accessed: May 23, 2024. [Online]. Available: https://openurl.ebsco.com/EPDB%3Agcd%3A13%3A17589741/detailv2?sid=ebsco%3Aplink%3Ascholar&id=ebsco%3Agcd%3A86661247&crl=c
Y. tai Yao, L. xian He, N. xin Fang, and J. Ma, “Anesthetic Induction With Etomidate in Cardiac Surgical Patients: A PRISMA-Compliant Systematic Review and Meta-Analysis,” J Cardiothorac Vasc Anesth, vol. 35, no. 4, pp. 1073–1085, Apr. 2021, doi: 10.1053/J.JVCA.2020.11.068.
A. Criado, J. Maseda, E. Navarro, A. Escarpa, and F. Avello, “INDUCTION OF ANAESTHESIA WITH ETOMIDATE: HAEMODYNAMIC STUDY OF 36 PATIENTS,” Br J Anaesth, vol. 52, no. 8, pp. 803–806, Aug. 1980, doi: 10.1093/BJA/52.8.803.
S. A. Forman and D. S. Warner, “Clinical and Molecular Pharmacology of Etomidate,” Anesthesiology, vol. 114, no. 3, pp. 695–707, Mar. 2011, doi: 10.1097/ALN.0B013E3181FF72B5.
A. N. Hildreth, V. A. Mejia, R. A. Maxwell, P. W. Smith, B. W. Dart, and D. E. Barker, “Adrenal suppression following a single dose of etomidate for rapid sequence induction: A prospective randomized study,” Journal of Trauma - Injury, Infection and Critical Care, vol. 65, no. 3, pp. 573–578, Sep. 2008, doi: 10.1097/TA.0B013E31818255E8.
L. Hüter, T. Schreiber, M. Gugel, and K. Schwarzkopf, “Low-dose intravenous midazolam reduces etomidate-induced myoclonus: A prospective, randomized study in patients undergoing elective cardioversion,” Anesth Analg, vol. 105, no. 5, pp. 1298–1302, 2007, doi: 10.1213/01.ANE.0000287248.25610.C0.
P. Zanos et al., “Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms,” Pharmacol Rev, vol. 70, no. 3, pp. 621–660, Jul. 2018, doi: 10.1124/PR.117.015198.
S. Mihaljević, M. Pavlović, K. Reiner, and M. Ćaćić, “Therapeutic mechanisms of ketamine,” Psychiatr Danub, vol. 32, no. 3–4, pp. 325–333, 2021, doi: 10.24869/PSYD.2020.325.
S. Natoli, “The multiple faces of ketamine in anaesthesia and analgesia,” Drugs Context, vol. 10, Apr. 2021, doi: 10.7573/DIC.2020-12-8.
A. Conway, K. Chang, S. Mafeld, and J. Sutherland, “Midazolam for sedation before procedures in adults and children: a systematic review update,” Syst Rev, vol. 10, no. 1, pp. 1–12, Dec. 2021, doi: 10.1186/S13643-021-01617-5/TABLES/4.
E. Sigel and M. E. Steinmann, “Structure, function, and modulation of GABAA receptors,” Journal of Biological Chemistry, vol. 287, no. 48, pp. 40224–40231, Nov. 2012, doi: 10.1074/jbc.R112.386664.
P. Howard, R. Twycross, J. Shuster, M. Mihalyo, and A. Wilcock, “Benzodiazepines,” J Pain Symptom Manage, vol. 47, no. 5, pp. 955–964, 2014, doi: 10.1016/j.jpainsymman.2014.03.001.
A. Editors, E. Abd El Hady Algharably, U. Gundert-Remy, J.-U. Peter, P. Dieudonné, and O. Zolk, “Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example,” Pharmaceuticals 2024, Vol. 17, Page 473, vol. 17, no. 4, p. 473, Apr. 2024, doi: 10.3390/PH17040473.
J. J. Rasimas, V. Kivovich, K. K. Sachdeva, and J. W. Donovan, “Antagonizing the errors of history: bedside experience with flumazenil,” Toxicol Commun, vol. 4, no. 1, pp. 25–39, Jan. 2020, doi: 10.1080/24734306.2020.1752551.
A. Kreshak and S. Munday, “Flumazenil,” Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient, pp. 2811–2818, Jun. 2017, doi: 10.1007/978-3-319-17900-1_152.
A. S. Razavizadeh, N. Zamani, P. Ziaeefar, S. Ebrahimi, and H. Hassanian-Moghaddam, “Protective effect of flumazenil infusion in severe acute benzodiazepine toxicity: a pilot randomized trial,” Eur J Clin Pharmacol, vol. 77, no. 4, pp. 547–554, Apr. 2021, doi: 10.1007/S00228-020-03031-7/METRICS.
J. C. Hong, “Midazolam: Mechanism and perioperative applications,” Treatments, Mechanisms, and Adverse Reactions of Anesthetics and Analgesics, pp. 131–138, Jan. 2022, doi: 10.1016/B978-0-12-820237-1.00014-4.
H. Allonen, G. Ziegler, and U. Klotz, “Midazolam kinetics,” Clin Pharmacol Ther, vol. 30, no. 5, pp. 653–661, 1981, doi: 10.1038/CLPT.1981.217.
T. E. Miller and T. J. Gan, “Total Intravenous Anesthesia and Anesthetic Outcomes,” J Cardiothorac Vasc Anesth, vol. 29, no. S1, pp. S11–S15, Jun. 2015, doi: 10.1053/j.jvca.2015.01.022.
A. F. Nimmo et al., “Guidelines for the safe practice of total intravenous anaesthesia (TIVA),” Anaesthesia, vol. 74, no. 2, pp. 211–224, Feb. 2019, doi: 10.1111/ANAE.14428.
J. Beverstock et al., “A Comparison of Volatile Anesthesia and Total Intravenous Anesthesia (TIVA) Effects on Outcome From Cardiac Surgery: A Systematic Review and Meta-Analysis,” J Cardiothorac Vasc Anesth, vol. 35, no. 4, pp. 1096–1105, Apr. 2021, doi: 10.1053/J.JVCA.2020.10.036.
F. Guarracino et al., “Target controlled infusion: TCI.,” Minerva Anestesiol, vol. 71, no. 6, pp. 335–337, Jun. 2005, doi: 10.1007/s00101-008-1332-z.
H. Schwilden and J. Schüttler, “Target controlled anaesthetic drug dosing,” Handb Exp Pharmacol, vol. 182, pp. 425–450, 2008, doi: 10.1007/978-3-540-74806-9_20.
G. Landoni et al., “Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery,” New England Journal of Medicine, vol. 380, no. 13, pp. 1214–1225, Mar. 2019, doi: 10.1056/NEJMOA1816476.
W. Sukhupragarn, P. Leurcharusmee, and T. Sotthisopha, “Cardiovascular Effects of Volatile Induction and Maintenance of Anesthesia (VIMA) and Total Intravenous Anesthesia (TIVA) for Laryngeal Mask Airway (LMA) Anesthesia: A Comparison Study,” J Med Assoc Thai, vol. 98, no. 4, pp. 388–93, 2015.
E. L. Ong, J. W. Chiu, J. L. Chong, and K. M. Kwan, “Volatile induction and maintenance (VIMA) versus total intravenous anaesthesia (TIVA) for minor gynaecological procedures,” Ambul Surg, vol. 8, no. 1, pp. 37–40, Jan. 2000, doi: 10.1016/S0966-6532(99)00030-X.
J. Chmielewski et al., “Anesthetic gases. Application, environmental exposure and ways of risk reduction,” Przemysl Chemiczny, vol. 97, no. 10, pp. 1760–1763, Oct. 2018, doi: 10.15199/62.2018.10.25.
A. F. Merry et al., “Multimodal system designed to reduce errors in recording and administration of drugs in anaesthesia: prospective randomised clinical evaluation,” BMJ, vol. 343, no. 7826, Sep. 2011, doi: 10.1136/BMJ.D5543.
C. Tornero Tornero, L. E. Fernández Rodríguez, and J. Orduña Valls, “Multimodal analgesia and regional anaesthesia,” Revista Española de Anestesiología y Reanimación (English Edition), vol. 64, no. 7, pp. 401–405, Aug. 2017, doi: 10.1016/J.REDARE.2017.01.007.
K. Krysta, “Bezpieczne i skuteczne stosowanie benzodiazepin w zaburzeniach psychiatrycznych i towarzyszących im innych schorzeniach,” Psychiatria, vol. 11, no. 1, pp. 9–14, 2014, Accessed: May 26, 2024. [Online]. Available: https://journals.viamedica.pl/psychiatria/article/view/38032/32029
S. A. Stewart, “Effects of Benzodiazepines on Cognition The Effects of Benzodiazepines on Cognition,” J Clin Psychiatry, 2005.
E. Sigel and M. E. Steinmann, “Structure, function, and modulation of GABAA receptors,” Journal of Biological Chemistry, vol. 287, no. 48, pp. 40224–40231, Nov. 2012, doi: 10.1074/JBC.R112.386664.
T. A. Simeone, S. D. Donevan, and J. M. Rho, “Molecular biology and ontogeny of γ-Aminobutyric acid (GABA) receptors in the mammalian central nervous system,” J Child Neurol, vol. 18, no. 1, pp. 39–48, Jan. 2003, doi: 10.1177/08830738030180012101.
A. Ghit, D. Assal, A. S. Al-Shami, and D. E. E. Hussein, “GABAA receptors: structure, function, pharmacology, and related disorders,” Journal of Genetic Engineering & Biotechnology, vol. 19, no. 1, Dec. 2021, doi: 10.1186/S43141-021-00224-0.
N. Noor, R. Legendre, A. Cloutet, A. Chitneni, G. Varrassi, and A. D. Kaye, “A comprehensive review of remimazolam for sedation,” Health Psychol Res, vol. 9, no. 1, p. 2021, 2021, doi: 10.52965/001C.24514.
J. Schüttler, A. Eisenried, M. Lerch, J. Fechner, C. Jeleazcov, and H. Ihmsen, “Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I pharmacokinetics and clinical pharmacodynamics,” Anesthesiol, vol. 132, pp. 636–651, 2020, doi: 10.1097/aln.0000000000003103.
M. DOI, “Remimazolam,” J Japan Soc Clin Anesth, vol. 34, no. 7, pp. 860–866, 2014, doi: 10.2199/jjsca.34.860.
K. Masui, T. Stöhr, M. Pesic, and T. Tonai, “A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice,” J Anesth, vol. 36, no. 4, pp. 493–505, Aug. 2022, doi: 10.1007/S00540-022-03079-Y/METRICS.
K. M. Kim, “Remimazolam: pharmacological characteristics and clinical applications in anesthesiology,” Anesth Pain Med (Seoul), vol. 17, no. 1, p. 1, Jan. 2022, doi: 10.17085/APM.21115.
S. J. Keam, “Remimazolam: First Approval,” Drugs, vol. 80, no. 6, pp. 625–633, Apr. 2020, doi: 10.1007/S40265-020-01299-8.
S. H. Kim and J. Fechner, “Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent,” Korean J Anesthesiol, vol. 75, no. 4, pp. 307–315, Aug. 2022, doi: 10.4097/kja.22297.
K. M. Kim, “Remimazolam: pharmacological characteristics and clinical applications in anesthesiology,” Anesthesia and Pain Medicine, vol. 17, no. 1. Korean Society of Anesthesiologists, pp. 1–11, Jan. 01, 2022. doi: 10.17085/apm.21115.
A. Lee and M. Shirley, “Remimazolam: A Review in Procedural Sedation,” Drugs, vol. 81, no. 10, pp. 1193–1201, Jul. 2021, doi: 10.1007/s40265-021-01544-8.
S. H. Kim and J. Fechner, “Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent,” Korean J Anesthesiol, vol. 75, no. 4, p. 307, Aug. 2022, doi: 10.4097/KJA.22297.
J. R. Sneyd and A. E. Rigby-Jones, “Remimazolam for anaesthesia or sedation,” Curr Opin Anaesthesiol, vol. 33, no. 4, pp. 506–511, Aug. 2020, doi: 10.1097/ACO.0000000000000877.
S. Dessai, S. Ninave, and A. Bele, “The Rise of Remimazolam: A Review of Pharmacology, Clinical Efficacy, and Safety Profiles.,” Cureus, vol. 16, no. 3, p. e57260, Mar. 2024, doi: 10.7759/cureus.57260.
A. Lee and M. Shirley, “Remimazolam: A Review in Procedural Sedation,” Drugs, vol. 81, no. 10, pp. 1193–1201, Jul. 2021, doi: 10.1007/s40265-021-01544-8.
D. M. Paton, “Remimazolam: a short-acting benzodiazepine for procedural sedation.,” Drugs Today (Barc), vol. 57, no. 5, pp. 337–346, May 2021, doi: 10.1358/DOT.2021.57.5.3264119.
Q. Hu, X. Liu, C. Wen, D. Li, and X. Lei, “Remimazolam: An Updated Review of a New Sedative and Anaesthetic,” Drug Des Devel Ther, vol. 16, p. 3957, 2022, doi: 10.2147/DDDT.S384155.
A. Eisenried, J. Schüttler, M. Lerch, H. Ihmsen, and C. Jeleazcov, “Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male VolunteersPart II. Pharmacodynamics of Electroencephalogram Effects,” Anesthesiology, vol. 132, no. 4, pp. 652–666, Apr. 2020, doi: 10.1097/ALN.0000000000003102.
H. R. Wiltshire, G. J. Kilpatrick, G. S. Tilbrook, and K. M. Borkett, “A placebo-and midazolam-controlled phase i single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. population pharmacokinetic and pharmacodynamic modeling and simulation,” Anesth Analg, vol. 115, no. 2, pp. 284–296, Aug. 2012, doi: 10.1213/ANE.0B013E318241F68A.
G. J. Kilpatrick et al., “CNS 7056: A novel ultra-short-acting benzodiazepine,” Anesthesiology, vol. 107, no. 1, pp. 60–66, Jul. 2007, doi: 10.1097/01.ANES.0000267503.85085.C0.
L. J. Antonik, D. R. Goldwater, G. J. Kilpatrick, G. S. Tilbrook, and K. M. Borkett, “A placebo-and midazolam-controlled phase i single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. safety, efficacy, and basic pharmacokinetics,” Anesth Analg, vol. 115, no. 2, pp. 274–283, Aug. 2012, doi: 10.1213/ANE.0B013E31823F0C28.
M. T. Worthington et al., “A phase ib, dose-finding study of multiple doses of remimazolam (cns 7056) in volunteers undergoing colonoscopy,” Anesth Analg, vol. 117, no. 5, pp. 1093–1100, Nov. 2013, doi: 10.1213/ANE.0B013E3182A705AE.
K. M. C. Borkett et al., “A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal Endoscopy,” Anesth Analg, vol. 120, no. 4, pp. 771–780, Apr. 2015, doi: 10.1213/ANE.0000000000000548.
D. J. Pambianco et al., “A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy,” Gastrointest Endosc, vol. 83, no. 5, pp. 984–992, May 2016, doi: 10.1016/J.GIE.2015.08.062.
J. Schüttler, A. Eisenried, M. Lerch, J. Fechner, C. Jeleazcov, and H. Ihmsen, “Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male VolunteersPart I. Pharmacokinetics and Clinical Pharmacodynamics,” Anesthesiology, vol. 132, no. 4, pp. 636–651, Apr. 2020, doi: 10.1097/ALN.0000000000003103.
K. M. C. Borkett et al., “A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal Endoscopy,” Anesth Analg, vol. 120, no. 4, pp. 771–780, Apr. 2015, doi: 10.1213/ANE.0000000000000548.
M. T. Worthington et al., “A phase ib, dose-finding study of multiple doses of remimazolam (cns 7056) in volunteers undergoing colonoscopy,” Anesth Analg, vol. 117, no. 5, pp. 1093–1100, Nov. 2013, doi: 10.1213/ANE.0B013E3182A705AE.
L. J. Antonik, D. R. Goldwater, G. J. Kilpatrick, G. S. Tilbrook, and K. M. Borkett, “A placebo-and midazolam-controlled phase i single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. safety, efficacy, and basic pharmacokinetics,” Anesth Analg, vol. 115, no. 2, pp. 274–283, Aug. 2012, doi: 10.1213/ANE.0B013E31823F0C28.
H. R. Wiltshire, G. J. Kilpatrick, G. S. Tilbrook, and K. M. Borkett, “A placebo-and midazolam-controlled phase i single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. population pharmacokinetic and pharmacodynamic modeling and simulation,” Anesth Analg, vol. 115, no. 2, pp. 284–296, Aug. 2012, doi: 10.1213/ANE.0B013E318241F68A.
L. J. Antonik, D. R. Goldwater, G. J. Kilpatrick, G. S. Tilbrook, and K. M. Borkett, “A placebo-and midazolam-controlled phase i single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. safety, efficacy, and basic pharmacokinetics,” Anesth Analg, vol. 115, no. 2, pp. 274–283, Aug. 2012, doi: 10.1213/ANE.0B013E31823F0C28.
R. N. Upton, A. A. Somogyi, A. M. Martinez, J. Colvill, and C. Grant, “Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep,” BJA: British Journal of Anaesthesia, vol. 105, no. 6, pp. 798–809, Dec. 2010, doi: 10.1093/BJA/AEQ260.
A. M. Wesolowski, M. P. Zaccagnino, R. J. Malapero, A. D. Kaye, and R. D. Urman, “Remimazolam: Pharmacologic Considerations and Clinical Role in Anesthesiology,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 36, no. 9, pp. 1021–1027, Sep. 2016, doi: 10.1002/PHAR.1806.
H. R. Wiltshire, G. J. Kilpatrick, G. S. Tilbrook, and K. M. Borkett, “A placebo-and midazolam-controlled phase i single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. population pharmacokinetic and pharmacodynamic modeling and simulation,” Anesth Analg, vol. 115, no. 2, pp. 284–296, Aug. 2012, doi: 10.1213/ANE.0b013e318241f68a.
T. Stöhr et al., “Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment,” Br J Anaesth, vol. 127, no. 3, pp. 415–423, Sep. 2021, doi: 10.1016/J.BJA.2021.05.027.
W. K. Rogers and T. S. McDowell, “Remimazolam, a short-acting GABAA receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures,” IDrugs, vol. 13, no. 12, pp. 929–937, Dec. 2010.
T. Urabe et al., “Characterization of intracellular calcium mobilization induced by remimazolam, a newly approved intravenous anesthetic,” PLoS One, vol. 17, no. 2, p. e0263395, Feb. 2022, doi: 10.1371/JOURNAL.PONE.0263395.
V. Salmasi et al., “Relationship between Intraoperative Hypotension, Defined by Either Reduction from Baseline or Absolute Thresholds, and Acute Kidney and Myocardial Injury after Noncardiac SurgeryA Retrospective Cohort Analysis,” Anesthesiology, vol. 126, no. 1, pp. 47–65, Jan. 2017, doi: 10.1097/ALN.0000000000001432.
R. Yuan et al., “Efficacy of pretreatment with remimazolam on prevention of propofol-induced injection pain in patients undergoing gastroscopy,” Sci Rep, vol. 13, no. 1, Dec. 2023, doi: 10.1038/s41598-023-47151-3.
J. Y. Choi et al., “Comparison of remimazolam-based and propofol-based total intravenous anesthesia on postoperative quality of recovery: A randomized non-inferiority trial,” J Clin Anesth, vol. 82, Nov. 2022, doi: 10.1016/j.jclinane.2022.110955.
G. Hasegawa, N. Hirata, Y. Yoshikawa, and M. Yamakage, “Differential effects of remimazolam and propofol on heart rate variability during anesthesia induction,” J Anesth, vol. 36, no. 2, pp. 239–245, Apr. 2022, doi: 10.1007/S00540-022-03037-8.
X. An, T. Shen, X. Yin, J. Xu, Y. Zhang, and T. Wang, “The safety of remimazolam versus propofol in gastroscopic sedation: a meta-analysis,” BMC Anesthesiol, vol. 24, no. 1, Dec. 2024, doi: 10.1186/s12871-024-02422-y.
“Remimazolam: a new ultra short acting benzodiazepine 2”, doi: 10.15406/jaccoa.2016.04.00166.
J. R. Sneyd, P. L. Gambus, and A. E. Rigby-Jones, “Current status of perioperative hypnotics, role of benzodiazepines, and the case for remimazolam: a narrative review,” Br J Anaesth, vol. 127, no. 1, pp. 41–55, Jul. 2021, doi: 10.1016/j.bja.2021.03.028.
K. Tsurumi, S. Takahashi, Y. Hiramoto, K. Nagumo, T. Takazawa, and Y. Kamiyama, “Remimazolam anaphylaxis during anesthesia induction,” J Anesth, vol. 35, no. 4, pp. 571–575, Aug. 2021, doi: 10.1007/S00540-021-02934-8.
J. J. Vicari, “Sedation in the Ambulatory Endoscopy Center: Optimizing Safety, Expectations and Throughput,” Gastrointest Endosc Clin N Am, vol. 26, no. 3, pp. 539–552, Jul. 2016, doi: 10.1016/j.giec.2016.02.005.
V.-A. Dao, F. Schippers, and T. Stöhr, “Efficacy of remimazolam versus midazolam for procedural sedation: post hoc integrated analyses of three phase 3 clinical trials,” Endosc Int Open, vol. 10, no. 04, pp. E378–E385, Apr. 2022, doi: 10.1055/A-1743-1936.
D. K. Rex, R. Bhandari, D. G. Lorch, M. Meyers, F. Schippers, and D. Bernstein, “Safety and efficacy of remimazolam in high risk colonoscopy: A randomized trial,” Digestive and Liver Disease, vol. 53, no. 1, pp. 94–101, Jan. 2021, doi: 10.1016/j.dld.2020.10.039.
X. Liu et al., “The efficacy and safety of remimazolam tosilate versus etomidate-propofol in elderly outpatients undergoing colonoscopy: A prospective, randomized, single-blind, non-inferiority trial,” Drug Des Devel Ther, vol. 15, pp. 4675–4685, 2021, doi: 10.2147/DDDT.S339535.
W. Ahmer et al., “Remimazolam versus propofol for sedation in gastrointestinal endoscopy and colonoscopy within elderly patients: a meta-analysis of randomized controlled trials,” Eur J Clin Pharmacol, vol. 80, no. 4, pp. 493–503, Apr. 2024, doi: 10.1007/s00228-024-03624-6.
D. K. Rex et al., “A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy,” Gastrointest Endosc, vol. 88, no. 3, pp. 427-437.e6, Sep. 2018, doi: 10.1016/J.GIE.2018.04.2351.
N. J. Pastis et al., “Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy,” Chest, vol. 155, no. 1, pp. 137–146, Jan. 2019, doi: 10.1016/J.CHEST.2018.09.015.
K. Masui, “Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!!,” J Anesth, vol. 34, no. 4, pp. 479–482, Aug. 2020, doi: 10.1007/S00540-020-02755-1/METRICS.
M. Doi, K. Morita, J. Takeda, A. Sakamoto, M. Yamakage, and T. Suzuki, “Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial,” J Anesth, vol. 34, no. 4, pp. 543–553, Aug. 2020, doi: 10.1007/S00540-020-02788-6.
M. Doi, N. Hirata, T. Suzuki, H. Morisaki, H. Morimatsu, and A. Sakamoto, “Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial,” J Anesth, vol. 34, no. 4, pp. 491–501, Aug. 2020, doi: 10.1007/S00540-020-02776-W/METRICS.
W. Chen, S. Chen, and Y. Huang, “Induction and maintenance of procedural sedation in adults: focus on remimazolam injection,” Expert Rev Clin Pharmacol, vol. 14, no. 4, pp. 411–426, Apr. 2021, doi: 10.1080/17512433.2021.1901575.
F. Schippers et al., “Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users,” J Clin Pharmacol, vol. 60, no. 9, p. 1189, Sep. 2020, doi: 10.1002/JCPH.1614.
H. Sasaki, H. Hoshijima, and K. Mizuta, “Ringer’s acetate solution-induced precipitation of remimazolam,” Br J Anaesth, vol. 126, no. 3, pp. e87–e89, Mar. 2021, doi: 10.1016/J.BJA.2020.11.021.
C. Bai, M. Xu, Y. Guo, Y. Jin, and X. Zhao, “Clinical Application and Research Progress of Remimazolam for Pediatric Patients,” Drug Des Devel Ther, vol. Volume 18, pp. 1221–1229, Apr. 2024, doi: 10.2147/DDDT.S453440.
Opublikowane
11 września 2024
Prawa autorskie (c) 2024 Julia Stachowiak, Patryk Walocha, Martyna Szlenk, Michał Wilk
Licencja
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
